PER-023-09已完成未知
A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib
OVARTIS BIOSCIENSES PERU S.A.,0 个研究点目标入组 0 人开始时间: 2009年4月29日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 100（—）
- 性别
- All
入选标准
- •Male or female, age> 18 years;
- •ECOG of O, 1 or 2;
- •Diagnosis of CMM Ph + in chronic phase (HR) at the beginning of treatment with imatinib 400 mg
- •Patients with suboptimal response to 400 mg of imatinib, (the cytogenic analysis to document the suboptimal response must have been performed within a maximum of 8 weeks before the first dose of the drug under study)
- •Patients receiving 400 mg / day of a standard dose of imatinib for at least 6 months and no more than 18 months;
- •That they have not been given imatinib in doses higher than 400 mg daily;
- •The previous use of IFN-a is allowed for a maximum of 1 month;
- •The following laboratory results should exist: Creatinine <2.0 X LSN, Total Bilirubin <1.5 X LSN (<3.0 X LSN if related to the disease), AST and ALT (<2.5 X LSN (<5.0 X LSN if related to the disease), serum lipase <1.5 X LSN, alkaline phosphatase <2.5 X LSN (<5.0 X LSN if related to the disease), serum potassium, phosphorus, magnesium and calcium> LIN [normal lower limit] or with supplements before the first dose of the study drug;
排除标准
- •CML in accelerated phase or blast crisis;
- •Previous treatment with imatinib in combination with any other drug;
- •More than 18 months (+8 weeks) of treatment with 400 mg of imatinib daily;
- •Patients receiving doses of 300 mg of imatinib daily;
- •T3151 mutation previously documented;
- •Reach a previous PCyR or RCC with imatinib and have lost said response before entering the study;
- •Previous treatment with any other tyrosine kinase inhibitor except imatinib;
- •Cardiac functioning disorders
- •Treatment with potent CYP3A4 inducers (such as dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbitol, St. John´s wort), and treatment cannot be interrupted or changed to a different medication before starting to deliver the study drug . See Section 6.1.3 for a complete list of these medications;
- •Treatment with potent CYP3A4 inhibitors (such as erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil), and treatment cannot be interrupted or changed to a different drug before starting to deliver the study drug. See Section 6.1.3 for a complete list of these medications;
- •It should be avoided to include patients taking a medication that has been documented to prolong the QT interval. In case it is not possible to avoid or change for another medication, the patient should be carefully monitored, having an ECG test every 3 months once the study is started, or if there is a change in the dose or clinical symptoms appear;
- •Impaired gastrointestinal (GI) function or GI disease that can significantly alter the absorption of the study drug (such as ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, intolerance syndrome, surgery of the small intestine or gastric bypass surgery) .
- •History of acute pancreatitis within the year prior to admission to the study or clinical history of chronic pancreatitis.
- •Cytopathological infiltration in the confirmed CNS (in the absence of suspected CNS intervention, a lumbar puncture is not required).
- •Pregnant women, who are breastfeeding or of childbearing age without a negative serum pregnancy test in the selection phase.
- •Male or female patients of childbearing age who refuse to use effective contraceptive methods during the trial. Post-menopausal women must have presented amenorrhea for at least 12 months to be considered as unable to procreate.
- •Patients with a history of another primary malignant tumor that is currently of clinical importance or requires active intervention.
- •Patients with other clinically significant medical or surgical disorders, which, at the discretion of the researchers, may make participation impossible.
- •Use of research agents in the 28 days prior to participation in the study or intended use of a research agent during the study;
- •Patients who do not wish or cannot comply with the protocol.
研究者
相似试验
进行中（未招募）
不适用
A RANDOMIZED PHASE III STUDY OF IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIBIMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CML AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIBMedDRA version: 9.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaEUCTR2008-007054-35-FIovartis Pharma Services AG188
进行中（未招募）
不适用
A clinical study which compares the benefit of optimizing the dose ofimatinib (Gleevec/Glivec) with Nilotinib (Tasigna) in patients with chronicmyelogenous leukemia who have not optimally responded to standardtreatment with Imatinib.IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CML AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIBMedDRA version: 14.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007054-35-DEovartis Pharma Services AG188
已完成
3 期
Chronic MyelogenousLeukemia Suboptimal Response Study.CTRI/2011/05/001752ovartis HealthCare Private Limited
已完成
3 期
Phase III Randomized Study of Imatinib therapy in chornic phase chronic myeloid leukemia comparing standard dose-escalation with progressive dose-escalation (JALSG CML207study)Previously untreated Chronic-phase chronic myelogenous leukemiaJPRN-UMIN000000823Japan Adult Leukemia Study Group240
进行中（未招募）
1 期
A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and IM for patients with Chronic Myeloid Leukaemia (CML) in Major Cytogenetic Response (MCyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR) - CHOICES-CHlOroquine and Imatinib Combination to Eliminate Stem cellsChronic Myeloid LeukaemiaMedDRA version: 15.0Level: PTClassification code 10009013Term: Chronic myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014373-41-DEClinical Trial Center Aachen76